Homology Medicines, Inc., a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients, announced today that its Chief Executive Officer, Arthur Tzianabos, Ph.D., will be presenting at the Alliance for Regenerative Medicine’s 5th Annual Cell & Gene Therapy Investor Day on April 27, 2017 at The State Room in Boston, Massachusetts. … Read More »

The development of human therapeutics using gene editing technologies is an area of major interest that has recently received large public and private investments. The initial applications of gene editing technologies have largely focused on the treatment of monogenic disorders, but other areas, such as immuno-oncology, have also witnessed recently a growing interest from the biopharmaceutical industry. … Read More »

Open Menu